-
公开(公告)号：US20050014934A1
公开(公告)日：2005-01-20
申请号：US10822300
申请日：2004-04-09
申请人： Paul Hinton , Naoya Tsurushita , J. Tso , Maximiliano Vasquez
发明人： Paul Hinton , Naoya Tsurushita , J. Tso , Maximiliano Vasquez
CPC分类号： C07K16/249 , C07K16/00 , C07K16/082 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
-
公开(公告)号：US20050142131A1
公开(公告)日：2005-06-30
申请号：US10497475
申请日：2002-04-26
申请人： Paul Hinton , Maximiliano Vasquez
发明人： Paul Hinton , Maximiliano Vasquez
IPC分类号： C07K16/18 , C12N5/02 , A61K39/395 , C07K16/44
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , Y02A50/407
摘要： Humanized forms of mouse antibody 10D5 that retain the binding properties of mouse 10D5 are disclosed. Also disclosed closed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.
摘要翻译： 公开了保留小鼠10D5的结合特性的小鼠抗体10D5的人源化形式。 还公开封闭的是制备人源化抗体的方法，用于制备人源化抗体的中间体，包括核苷酸序列，载体，转化的宿主细胞，以及使用人源化抗体治疗，预防，缓解，逆转或以其他方式改善症状或 病理学或两者，与唐氏综合征或临床前或临床阿尔茨海默病或脑淀粉样血管病相关。
-
公开(公告)号：US20050032114A1
公开(公告)日：2005-02-10
申请号：US10687118
申请日：2003-10-15
申请人： Paul Hinton , Naoya Tsurushita , J. Tso , Maximiliano Vasquez
发明人： Paul Hinton , Naoya Tsurushita , J. Tso , Maximiliano Vasquez
CPC分类号： C07K16/082 , C07K16/00 , C07K16/249 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
-
公开(公告)号：US07365168B2
公开(公告)日：2008-04-29
申请号：US11102621
申请日：2005-04-08
申请人： Paul Hinton , Naoya Tsurushita , J. Yun Tso , Maximiliano Vasquez
发明人： Paul Hinton , Naoya Tsurushita , J. Yun Tso , Maximiliano Vasquez
CPC分类号： C07K16/00 , C07K16/082 , C07K16/249 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
-
5.发明申请Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis 有权通过诱变改变抗体的FcRn结合亲和力或血清半衰期公开(公告)号：US20050276799A1
公开(公告)日：2005-12-15
申请号：US11102621
申请日：2005-04-08
申请人： Paul Hinton , Naoya Tsurushita , J. Tso , Maximiliano Vasquez
发明人： Paul Hinton , Naoya Tsurushita , J. Tso , Maximiliano Vasquez
CPC分类号： C07K16/00 , C07K16/082 , C07K16/249 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
摘要翻译： 本发明提供IgG类型的修饰抗体，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一个不同于 其存在于未修饰的抗体中，从而与未修饰的抗体相比改变对FcRn的结合亲和力和/或血清半衰期。
-
公开(公告)号：US08877688B2
公开(公告)日：2014-11-04
申请号：US12404059
申请日：2009-03-13
IPC分类号： C40B40/08
CPC分类号： C12N15/1093 , C07K16/00 , C07K16/005 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C40B40/08
摘要： The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system, with or without DH segments derived from other species, and are based on rational design informed by examination of publicly available databases of antibody sequences.
摘要翻译： 本发明克服了通过专门设计具有定向序列和长度多样性的文库来生成抗体编码多核苷酸文库的已知方法中的不足之处。 图书馆旨在反映人类免疫系统自然产生的免疫缺陷病毒库，具有或不具有衍生自其他物种的DH区段，并且基于通过检查可公开获得的抗体序列数据库而得出的合理设计。
-
7.发明授权Methods of treatment by administering antibodies that bind colony stimulating factor 1 receptor (CSF1R) 有权通过施用结合集落刺激因子1受体（CSF1R）的抗体进行治疗的方法公开(公告)号：US08747845B2
公开(公告)日：2014-06-10
申请号：US13464503
申请日：2012-05-04
申请人： Justin Wong , Maximiliano Vasquez
发明人： Justin Wong , Maximiliano Vasquez
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： C07K16/2866 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/11 , C12N15/63
摘要： Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
摘要翻译： 提供了结合CSF1R的抗体。 还提供能够形成结合CSF1R的抗体的抗体重链和轻链。 提供编码CSF1R抗体的多核苷酸。 还提供了编码抗体重链和灯链的多核苷酸。 提供使用抗CSF1R抗体的方法。 这些方法包括但不限于治疗类风湿性关节炎，骨丢失和多发性硬化症的方法。
-
公开(公告)号：US08691730B2
公开(公告)日：2014-04-08
申请号：US12210072
申请日：2008-09-12
IPC分类号： C40B40/08
CPC分类号： C07K16/18 , C07K16/005 , C07K16/40 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C40B40/10
摘要： The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.
摘要翻译： 本发明克服了通过专门设计具有定向序列和长度多样性的文库来生成抗体编码多核苷酸文库的已知方法中的不足之处。 这些图书馆旨在反映由人类免疫系统自然产生的免疫缺陷文库，并且基于通过检查公开可得到的人抗体序列数据库的合理设计。
-
公开(公告)号：US20110158986A1
公开(公告)日：2011-06-30
申请号：US12976282
申请日：2010-12-22
申请人： David M. Holtzman , Ronald DeMattos , Kelly R. Bales , Steven M. Paul , Naoya Tsurushita , Maximiliano Vasquez
发明人： David M. Holtzman , Ronald DeMattos , Kelly R. Bales , Steven M. Paul , Naoya Tsurushita , Maximiliano Vasquez
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide Aβ.
摘要翻译： 描述了以预防和治疗形成淀粉样斑块为特征的病症的治疗方法。 该方法采用螯合可溶性A＆Bgr的人源化抗体 来自人类生物流体的肽或其优选特异性结合淀粉样蛋白β肽A＆bgr的第13-28位含有的表位。
-
公开(公告)号：US07851600B2
公开(公告)日：2010-12-14
申请号：US11581944
申请日：2006-10-16
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
摘要翻译： 本发明涉及抗CCR5抗体，其包含（i）两条轻链，每条轻链包含命名为pVK：HuPRO140-VK（ATCC保藏号PTA-4097）的质粒的表达产物，和（ii）两条重链 每个重链包含称为pVg1：HuPRO140HG2-VH（ATCC保藏号PTA-4098）的质粒或称为pVg1：HuPRO140（mutB + D + I）-VH（ATCC保藏号PTA-4099）的质粒的表达产物 ）或其与人细胞表面上的CCR5结合的片段。
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.056 秒)
